Skip to main content

Voyager Therapeutics, Inc. (VYGR)

NASDAQ: VYGR · IEX Real-Time Price · USD
3.93
+0.14 (3.69%)
After-hours:Oct 22, 2021 7:59 PM EDT
3.79
-0.12 (-3.07%)
At close: Oct 22, 4:00 PM
Market Cap143.78M
Revenue (ttm)132.24M
Net Income (ttm)17.92M
Shares Out37.58M
EPS (ttm)0.47
PE Ratio8.01
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,614,120
Open3.87
Previous Close3.91
Day's Range3.70 - 3.89
52-Week Range2.46 - 12.00
Beta1.04
AnalystsBuy
Price Target7.07 (+86.5%)
Est. Earnings DateNov 8, 2021

About VYGR

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's dise...

IndustryBiotechnology
IPO DateNov 11, 2015
CEOG. Andre Turenne
Employees177
Stock ExchangeNASDAQ
Ticker SymbolVYGR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for VYGR stock is "Buy." The 12-month stock price forecast is 7.07, which is an increase of 86.54% from the latest price.

Price Target
$7.07
(86.54% upside)
Analyst Consensus: Buy

News

Voyager Posts Encouraging Preclinical Data For CNS-Directed Gene Therapy

Voyager Therapeutics Inc (NASDAQ: VYGR) has announced the presentation of preclinical data of GBA1 gene replacement therapy. The data demonstrated that a single intravenous (IV) dose of GBA1 gene replac...

3 days ago - Benzinga

Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress...

Single AAV intravenous dose achieved widespread CNS distribution and sustained correction of GCase activity in multiple brain regions Single AAV intravenous dose achieved widespread CNS distribution and...

3 days ago - GlobeNewsWire

Top Biotech Penny Stocks to Watch With High Volume Right Now

Are these high volume biotech penny stocks worth adding to your watchlist right now? The post Top Biotech Penny Stocks to Watch With High Volume Right Now appeared first on Penny Stocks to Buy, Picks, N...

Other symbols:ADXSRSLS
2 weeks ago - PennyStocks

Implied Volatility Surging for Voyager (VYGR) Stock Options

Investors need to pay close attention to Voyager (VYGR) stock based on the movements in the options market lately.

2 weeks ago - Zacks Investment Research

VYGR Stock: The Huge Licensing Deal Sending Voyager Therapeutics Rocketing Higher

Here's the big licensing news that's sending shares of VYGR stock higher today as investors reassess this company's value moving forward. The post VYGR Stock: The Huge Licensing Deal Sending Voyager The...

2 weeks ago - InvestorPlace

Here's why Voyager Therapeutics is up 55%

Voyager Therapeutics Inc (NASDAQ: VYGR) announced that the group had inked a license option agreement that allows Pfizer Inc. (NYSE: PFE). As news of the deal became official and was doing the rounds, t...

2 weeks ago - Invezz

Voyager Therapeutics Stock Soars On License Option Pact With Pfizer

Voyager Therapeutics Inc (NASDAQ: VYGR) has announced licensing option agreement with Pfizer Inc (NYSE: PFE) for capsids generated from Voyager's RNA-driven TRACER screening technology. Related:   Voyag...

2 weeks ago - Benzinga

Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enabl...

Voyager receives $30 million up front with potential option exercise fees and milestone payments of up to $600 million plus product sales-based royalties

2 weeks ago - GlobeNewsWire

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

Other symbols:MGTXQURESLDBSRPT
1 month ago - Zacks Investment Research

Voyager Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies, toda...

1 month ago - GlobeNewsWire

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -6.67% and -66.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER™ AAV Capsid and Vectorize...

Proprietary AAV capsids to power second-generation efforts in Huntington's disease and ALS, pre-clinical programs in spinal muscular atrophy and diseases linked to GBA1 mutations

2 months ago - GlobeNewsWire

Analysts Estimate Voyager Therapeutics (VYGR) to Report a Decline in Earnings: What to Look Out for

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Voyager CEO Resigns After Company Turns Back To Discovery-Stage

Voyager Therapeutics, Inc (NASDAQ: VYGR) CEO and President Andre Turenne will step down as the beleaguered company announced it would move focus to early, discovery-stage efforts. The company's CMO and ...

5 months ago - Benzinga

Voyager Therapeutics Announces Strategic Shift and Leadership Transitions

Company focusing on rapidly moving VY-HTT01 into clinical development for Huntington's disease and maximizing opportunities created by TRACER TM gene therapy technology platform and next-generation targ...

5 months ago - GlobeNewsWire

Voyager Therapeutics' Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS Disorders

Voyager Therapeutics Inc (NASDAQ: VYGR) has announced new preclinical data characterizing the durable expression and activity of a vectorized anti-tau antibody. The results will be presented at the Amer...

5 months ago - Benzinga

Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Ant...

Findings to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy

5 months ago - GlobeNewsWire

Voyager Therapeutics' Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transd...

CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for serious neurologica...

5 months ago - GlobeNewsWire

Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 18.31% and 35.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates

- On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington's disease in the fourth quarter of 2021

5 months ago - GlobeNewsWire

Earnings Preview: Voyager Therapeutics (VYGR) Q1 Earnings Expected to Decline

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Strength Seen in Voyager Therapeutics (VYGR): Can Its 16.5% Jump Turn into More Strength?

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more ...

5 months ago - Zacks Investment Research

Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today

Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCR...

Other symbols:AXSMQURECRSPRVPH
5 months ago - Benzinga

Voyager Therapeutics' Stock Jumps As FDA Lifts Clinical Hold For Huntington's Disease Gene Therapy

Today FDA has removed the clinical hold on one more gene therapy study, this time for Voyager Therapeutics Inc's (NASDAQ: VYGR) investigational new drug application for VY-HTT01, a gene therapy candidat...

5 months ago - Benzinga

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc....

Los Angeles, California--(Newsfile Corp. - March 24, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeuti...

6 months ago - Newsfile Corp